Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,028 Cr
Revenue (TTM)
₹1,787 Cr
Net Profit (TTM)
₹99 Cr
ROE
11.8 %
ROCE
15.5 %
P/E Ratio
20.4
P/B Ratio
1.7
Industry P/E
32.03
EV/EBITDA
13.3
Div. Yield
0.5 %
Debt to Equity
0.1
Book Value
₹22.3
EPS
₹1.4
Face value
2
Shares outstanding
547,953,699
CFO
₹187.44 Cr
EBITDA
₹991.12 Cr
Net Profit
₹580.70 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Morepen Lab
| -9.9 | -2.1 | -9.4 | -25.1 | 14.0 | 3.2 | 4.0 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Morepen Lab
| -48.1 | 59.2 | 28.3 | -32.7 | 84.7 | 95.5 | -29.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Morepen Lab
|
37.0 | 2,028.0 | 1,786.8 | 100.3 | 5.4 | 6.5 | 20.4 | 1.7 |
| 343.2 | 3,134.2 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.5 | 2.1 | |
| 949.8 | 11,646.5 | 2,512.3 | 543.7 | 28.3 | 19.3 | 21.4 | 3.7 | |
| 358.0 | 6,205.7 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.1 | 4.8 | |
| 1,092.3 | 11,428.8 | 1,158.7 | 309.6 | 31.9 | 17.3 | 36.6 | 6.0 | |
| 1,478.2 | 28,010.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 32.2 | 5.6 | |
| 11,995.0 | 15,402.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 86 | 9.3 | |
| 1,879.7 | 3,107.9 | 673.7 | 202.6 | 17.6 | 19.4 | 15.3 | 5.4 | |
| 751.6 | 3,460.7 | 588.5 | 102.9 | 22.1 | 12.7 | 34.1 | 4.1 | |
| 134.0 | 3,532.5 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.3 |
2 min read•By News Desk
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic,... anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India. Read more
Incorporated
1984
Chairman
Sushil Suri
Managing Director
Sushil Suri
Group
Morepen
Headquarters
Solan Dist, Himachal Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClosure Of Credit Facility - Kotak Mahindra Bank
11-Mar-2026Unsecured Term Loan Facility From Woori Bank
11-Feb-2026Q3 And Nine Months FY26 Results
10-Feb-2026
The share price of Morepen Laboratories Ltd is ₹36.99 (NSE) and ₹37.01 (BSE) as of 20-Mar-2026 IST. Morepen Laboratories Ltd has given a return of 14.03% in the last 3 years.
The P/E ratio of Morepen Laboratories Ltd is 20.39 times as on 20-Mar-2026, a 36 discount to its peers’ median range of 32.03 times.
The P/B ratio of Morepen Laboratories Ltd is 1.66 times as on 20-Mar-2026, a 20 discount to its peers’ median range of 2.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.21
|
2.27
|
|
2024
|
22.36
|
2.54
|
|
2023
|
33.94
|
1.74
|
|
2022
|
17.20
|
3.17
|
|
2021
|
14.89
|
3.80
|
The 52-week high and low of Morepen Laboratories Ltd are Rs 70.50 and Rs 33.50 as of 21-Mar-2026.
Morepen Laboratories Ltd has a market capitalisation of ₹ 2,028 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Morepen Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.